Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021

Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) is set to release its fourth quarter and year-end 2020 financial results on February 24, 2021, post-market. A conference call will follow at 4:30 PM ET to discuss these results and provide a general business update. The call can be accessed via dial-in or through an audio webcast on Aurinia's website. The company is known for its FDA-approved treatment, LUPKYNIS™, targeting adult patients with active lupus nephritis.

Positive

• Aurinia has introduced LUPKYNIS™, the first FDA-approved oral therapy for lupus nephritis.

Negative

• None.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia’s management team will host a conference call to discuss the Company’s financial results and to provide a general business update.

The conference call and webcast is scheduled for February 24, 2021 at 4:30pm ET. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005243/en/

FAQ

When will Aurinia Pharmaceuticals release its financial results?

Aurinia will release its fourth quarter and year-end 2020 financial results on February 24, 2021.

What time is the conference call for Aurinia's financial results?

The conference call is scheduled for February 24, 2021, at 4:30 PM ET.

How can I access the conference call for Aurinia Pharmaceuticals?

The conference call can be accessed by dialing +1-877-407-9170 or through an audio webcast on Aurinia's corporate website.

What is LUPKYNIS™?

LUPKYNIS™ is Aurinia’s FDA-approved oral therapy for treating active lupus nephritis.